SCHEMBL8682181

SCHEMBL8682181

C[SiH](C)OC(c1ccc(C=O)cn1)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
POLB P06746 1/20 0.32
KCNJ1 P48048 1/20 0.31
ALDH1A3 P47895 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507789 0.77 GBA1 (0.31)
SCHEMBL3387686 0.77 KDM4E (0.36) KDM4EPOLB
SCHEMBL8546443 0.77 ESR1 (0.32)
SCHEMBL8683925 0.77 ESR1 (0.35)
SCHEMBL979051 0.76 TYR (0.46) ALDH1A1ALDH1A3NPSR1
SCHEMBL8546445 0.75 EGFR (0.30)
SCHEMBL6481337 0.75 SMO (0.31)
SCHEMBL6475290 0.73 KDM4E (0.36) KDM4EALDH1A1L3MBTL1
SCHEMBL507627 0.73 MAPK1 (0.33) ALDH1A1
SCHEMBL5036986 0.72 ALDH1A1 (0.47) KDM4EALDH1A1L3MBTL1POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162802-B1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME NIHON MEDIPHYSICS CO LTD (JP) 2020-08-19 EP disclosed
CN-106458995-B 2- (3-pyridyl) -1H-benzimidazole derivative compound and medicine containing the same 日本医事物理股份有限公司 2019-12-20 CN disclosed
US-10358434-B2 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same NIHON MEDI-PHYSICS CO., LTD. (JP) 2019-07-23 US disclosed
US-20190169169-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICAMENT CONTAINING SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2019-06-06 US disclosed
US-10189815-B2 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same NIHON MEDI-PHYSICS CO., LTD. (JP) 2019-01-29 US disclosed
US-20170158668-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2017-06-08 US disclosed
EP-3162802-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME Nihon Medi-Physics Co., Ltd. (JP) 2017-05-03 EP disclosed
US-5821255-A REGULATING THE SECRETION OF CORTICOTROPIN, BETA-ENDORPHIN OR PEPTIDES DERIVED FROM PROOPIOMELANOCORTIN SANOFI (FR) 1998-10-13 US disclosed
US-5602132-A USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR SANOFI (FR) 1997-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169169-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICAMENT CONTAINING SAME XDH, CYP11B2, GOT2 KDM4E 2259/4885ALDH1A1 1225/4885L3MBTL1 4465/4885
US-20170158668-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME XDH, REN, BRD4 KDM4E 1903/4885ALDH1A1 1425/4885L3MBTL1 4265/4885
US-10358434-B2 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same XDH, CYP11B2, GOT2 KDM4E 2259/4885ALDH1A1 1225/4885L3MBTL1 4465/4885
US-10189815-B2 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same XDH, REN, BRD4 KDM4E 1903/4885ALDH1A1 1425/4885L3MBTL1 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.